Opinion: With News of Another Failed Trial, a Cure for Alzheimer’s May Have More To Do With Corporate Finance Than Science
Heidi V. Pickett and David Weild weigh in on the financial obstacles that have stymied progress in Alzheimer’s drug development. Last month, Roche announced…